Journal of Clinical Apheresis · 2021 · 29 citations · 21 references
Life SciencesImmunologyNeurologyAutoimmunityImmunotherapyNeuroimmunologyAutoimmune DiseasesAutoimmune Neurological DisordersDemyelinating DiseasesDemyelinating DisordersMultiple SclerosisNeuroinflammationAutoimmune DemyelinationAutoimmune Neurological DiseaseChronic Inflammatory Demyelinating PolyradiculoneuropathyClinical Outcome MeasurementInflammatory DemyelinationMultiple Sclerosis TherapyTherapy Response MonitoringTreatment Response Criteria
BACKGROUND: Therapeutic plasma exchange (TPE) and immunoadsorption (IA) are first or second line treatment options in patients with neurological autoimmune diseases, including multiple sclerosis, neuromyelitis optica spectrum disorders (NMSOD), chronic inflammatory demyelinating polyneuropathy, acute inflammatory demyelinating polyradiculoneuropathy (Guillain-Barré syndrome), and autoimmune encephalitis. METHODS: In this prospective randomized controlled monocentric study, we assessed safety and efficacy of therapy with IA or TPE in patients with neurological autoimmune diseases. Treatment response was assessed using various neurological scores as well by measuring immunoglobulin and cytokine concentrations. Clinical outcome was evaluated by application of specific scores for the underlying diseases. RESULTS: A total of 32 patients were analyzed. Among these, 19 patients were treated with TPE and 13 patients with IA. IA and TPE therapy showed a comparable significant treatment response. In patients with MS and NMOSD, mean EDSS before and after treatment showed a significant reduction after treatment with IA. We observed a significant reduction of the pro-inflammatory cytokines IL-12, lL-17, IL-6, INF-γ, and tumor necrosis factor alpha during IA treatment, whereas this reduction was not seen in patients treated with TPE. CONCLUSIONS: In summary, both IA and TPE were effective and safe procedures for treating neurological autoimmune diseases. However, there was a trend towards longer therapy response in patients treated with IA compared to TPE, possibly related to a reduction in plasma levels of pro-inflammatory cytokines seen only in the IA-treated group.
21
Rating neurologic impairment in multiple sclerosis
John F. Kurtzke · Neurology · 1983 · 14.9K citations
Interobserver agreement for the assessment of handicap in stroke patients.
John C. van Swieten, Peter J. Koudstaal, Marieke C. Visser et al. · Stroke · 1988 · 6.5K citations · Full text
Life Sciences, Neurology, Functional Movement Assessment +14
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk, Brenda Banwell, Jeffrey L. Bennett et al. · Neurology · 2015 · 4.5K citations · Full text
Medicine, Neurology, Neuroscience +15
Anand Padmanabhan, Laura Connelly‐Smith, Nicole A. Aqui et al. · Journal of Clinical Apheresis · 2019 · 2.2K citations
Pharmacy, Immunology, Aphasia +7
CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHY
Richard AC Hughes, John Newsom–Davis, G D Perkin et al. · The Lancet · 1978 · 1.1K citations